Literature DB >> 10594749

High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas.

E S Bales1, C Dietrich, D Bandyopadhyay, D J Schwahn, W Xu, V Didenko, P Leiss, N Conrad, O Pereira-Smith, I Orengo, E E Medrano.   

Abstract

Cancer cells have abnormal cell cycle regulation which favors accelerated proliferation, chromosomal instability, and resistance to the senescence response. Although the p16INK4a locus is the most prominent susceptibility locus for familial melanomas, the low frequency of p16 mutations in sporadic melanomas suggests additional alterations in other cell cycle regulatory genes. Here we used primary melanoma tumors to reveal early cell cycle alterations that could be masked in advanced metastatic lesions due to their inherently high genetic instability. Unexpectedly, the cyclin-dependent kinase inhibitors p27KIP1 and/or p21Waf-1/SDI-1 were found to be expressed in 13 of 18 (72%) of the primary melanomas with a Breslow thickness greater than 0.076 mm. In general, p27 and/or p21 staining in the primary tumors correlated with low Ki-67 index. Importantly, most of the p21- and p27-positive tumors expressed high levels of cyclin D1 and cyclin E. In proliferating cells p27 is predominantly associated with cyclin D-CDK4 complexes, but does not inhibit the kinase activity, whereas in quiescent cells p27 is found associated with inactive CDK2 complexes. p27 was also expressed at high levels in proliferating primary melanomas in culture, and found to be associated with active cyclin E-CDK2 complexes containing high levels of cyclin E. It is thus likely that accumulation of cyclin E overcomes the potent inhibitory activity of p27 and p21 in CDK2 complexes. Of the primary melanomas with no indication of invasiveness, only three of 15 (20%) were positive for p27 and/or p21. We propose that high levels of p27 and p21 may confer upon melanoma tumors their characteristic resistance to conventional therapies. In turn, high levels of cyclins E and D1 may contribute to unlimited proliferation in primary melanomas that express the tumor suppressor p16INK4. J Invest Dermatol 113:1039-1046 1999

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594749     DOI: 10.1046/j.1523-1747.1999.00812.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  14 in total

1.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

2.  Activation of p21-Dependent G1/G2 Arrest in the Absence of DNA Damage as an Antiapoptotic Response to Metabolic Stress.

Authors:  L Alexis Hoeferlin; Natalia V Oleinik; Natalia I Krupenko; Sergey A Krupenko
Journal:  Genes Cancer       Date:  2011-09

3.  Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.

Authors:  Christopher Abdullah; Xiaolei Wang; Dorothea Becker
Journal:  Cell Cycle       Date:  2011-03-15       Impact factor: 4.534

4.  Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions.

Authors:  J Georgieva; P Sinha; D Schadendorf
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

5.  Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique.

Authors:  Guang Shan; Tian Tang
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

6.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.

Authors:  Suzanne Carreira; Jane Goodall; Laurence Denat; Mercedes Rodriguez; Paolo Nuciforo; Keith S Hoek; Alessandro Testori; Lionel Larue; Colin R Goding
Journal:  Genes Dev       Date:  2006-12-15       Impact factor: 11.361

7.  Cyclin D1 and D3 expression in melanocytic skin lesions.

Authors:  Ana Alekseenko; Anna Wojas-Pelc; Grzegorz J Lis; Alicja Furgał-Borzych; Grzegorz Surówka; Jan A Litwin
Journal:  Arch Dermatol Res       Date:  2010-05-23       Impact factor: 3.017

8.  Loss of heterozygosity at 12p13 and loss of p27KIP1 protein expression contribute to melanoma progression.

Authors:  Christian Woenckhaus; Irina Fenic; Jürgen Giebel; Sebastian Hauser; Klaus Failing; Joachim Woenckhaus; Thomas Dittberner; Micaela Poetsch
Journal:  Virchows Arch       Date:  2004-06-17       Impact factor: 4.064

9.  FBXW7 mutations in melanoma and a new therapeutic paradigm.

Authors:  Iraz T Aydin; Rachel D Melamed; Sarah J Adams; Mireia Castillo-Martin; Ahu Demir; Diana Bryk; Georg Brunner; Carlos Cordon-Cardo; Iman Osman; Raul Rabadan; Julide Tok Celebi
Journal:  J Natl Cancer Inst       Date:  2014-05-16       Impact factor: 13.506

10.  Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression.

Authors:  G E Piérard
Journal:  ISRN Dermatol       Date:  2012-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.